Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group studyChristophe Cellier, Ralph Raymond, Pekka Collin et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 101
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC studyMorgane Cheminant, Olivier Hermine, Julie Bruneau et al.|Gut|2018Cited by 62
616 - AMG 714 (Anti-IL-15 MAB) Halts the Progression of Aberrant Intraepithelial Lymphocytes in Refractory Celiac Disease type II (RCD-II): A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study Evaluating AMG 714 in Adult Patients with RCD-II/Pre-EATLChristophe Cellier, Chris J. Mulder, Tom van Gils et al.|Gastroenterology|2018Cited by 10